title: 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a S.I.T.I.L.O. multicentric study.
abstract: A multicentric study has been carried out on 120 patients affected by peritoneal carcinomatosis from colorectal cancer. Patients have been treated by cytoreductive surgery and intra-operative hyperthermic chemoperfusion (HIPEC) with cisplatin (CDDP) and mitomycin-c (MMC). A small group of patients were treated with oxaliplatin (LOHP) following the Elias et al. scheme [intravenous 5-fluorouracil (400 mg/m2) and leucovorin (20 mg/m2) followed by intraperitoneal perfusion with LOHP (460 mg/m2) in 2 l/m2, during 30 min at 43 degrees C]. CC-0 cytoreduction was achieved in 85.2% of the patients. Major morbidity and mortality was 22.5% and 3.3%, respectively. No G4 toxicity was registered. The three-year survival was 25.8%. The difference in survival evaluating complete cytoreduction (CC-0) vs. incomplete (CC1-2; residual tumor nodules greater than 2.5 mm) was statistically significant (p < 0.0001). Evaluating only the patients that could be cytoreduced to CC-0, the 3-year survival was raised to 33.5%. In our experience the peritoneal cancer index (PCI) has been demonstrated to be a weak prognostic factor reaching a statistical significance only after the exclusion of patients with resected hepatic metastases. The patients treated with oxaliplatin were alive and free-of-disease after a 16-month median follow-up.
authors.affiliation: Surgical Oncology, San Camillo-Forlanini Hospital, Rome, Italy. francescocavaliere@fastwebnet.it
authors.forename: F
authors.initials: F
authors.lastname: Cavaliere
authors.forename: M
authors.initials: M
authors.lastname: Valle
authors.forename: M
authors.initials: M
authors.lastname: De Simone
authors.forename: M
authors.initials: M
authors.lastname: Deraco
authors.forename: C R
authors.initials: CR
authors.lastname: Rossi
authors.forename: F
authors.initials: F
authors.lastname: Di Filippo
authors.forename: S
authors.initials: S
authors.lastname: Verzi
authors.forename: D
authors.initials: D
authors.lastname: Giannarelli
authors.forename: P
authors.initials: P
authors.lastname: Perri
authors.forename: P L
authors.initials: PL
authors.lastname: Pilati
authors.forename: M
authors.initials: M
authors.lastname: Vaira
authors.forename: S
authors.initials: S
authors.lastname: Di Filippo
authors.forename: A
authors.initials: A
authors.lastname: Garofalo
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D010478:Chemotherapy, Cancer, Regional Perfusion; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D006979:Hyperthermia, Induced; D002955:Leucovorin / Q000008:administration & dosage; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010534:Peritoneal Neoplasms / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D010537:Peritoneum / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil